AB SCIENCE |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.116 EUR | -2.45% |
|
-5.74% | -68.61% |
| 06-28 | AB Science: negative CHMP opinion for masitinib in ALS | CF |
| 06-03 | AB Science: share price falls on resumption of trading | CF |
Presenter SpeechAlain Moussy (Executives)[Foreign Language] And in English, welcome, everybody...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
AB Science specializes in research, development, and sales of kinase protein inhibitors (KPI), therapeutic drugs used in treating cancerous tumors, inflammatory and neuro-degenerative diseases in both humans and animals.
Sector
Pharmaceuticals
Calendar
2024-09-29
- Q2 2024 Earnings Release
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.116
EUR
Average target price
6.895
EUR
Spread / Average Target
+517.83%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -68.61% | 72.42M | |
| +7.39% | 72.4B | |
| +15.93% | 8.98B | |
| +17.59% | 4.28B | |
| -22.81% | 4.28B | |
| +25.93% | 4.01B | |
| +4.64% | 2.16B | |
| +9.09% | 1.95B | |
| -36.86% | 1.9B | |
| -0.50% | 1.64B |
- Stock Market
- Equities
- AB Stock
- News AB Science
- Transcript : AB Science S.A. - Special Call
